Brain Discovery For Better Recovery

Recovery Support for Your Journey

Neurotype’s NeuromarkR™ platform objectively measures brain responses to triggers for substance use, enabling personalized care and enhancing patient engagement.

Triggers linger for cravings, distress, and drug use

For many people recovering from Substance Use Disorder (SUD), seeing people, places, or things associated with past drug use can trigger future drug use. These triggers have a powerful influence on the recovery journey because the brain has become wired to respond to drug triggers as motivating, capable of causing cravings, distress, and drug use even after months or years of not using. Many people have trouble acknowledging the impact that triggers have on their feelings, thoughts, and behaviors, especially if they have difficulty describing their own emotions or may be uncomfortable with the stigma often associated with SUD.

Hope for Trigger Management

Despite the availability of valuable frontline SUD medications (e.g., buprenorphine or methadone for Opioid Use Disorder, bupropion or varenicline for chronic cigarette smoking, etc.), the majority of medicated patients return to drug use within months often because of triggers in their environment. Fortunately, Cognitive Behavioral Therapy (CBT), Mindfulness Based Therapies (MBTs), and other interventions can teach skills to help prevent drug use caused by triggers by reprogramming thought processes and brain reactions. However, less than 10% of medicated patients learn such skills. And, many patients prematurely discontinue or don’t benefit from such skill training due to a lack of self-awareness about the  subconscious and neurobiological risks associated with their own triggers.

A Brain Biomarker Craving Risk and Drug Use

Scientists have found a way to track and treat the risk of craving for drugs by measuring how the brain reacts to drug-related cues using Visual Evoked Potentials. To do this, they place sensors on a patient’s head and record brain activity while the patient looks at images of drugs and non-drug scenes. This information helps identify patients who are more likely to relapse and determines when they are most vulnerable to drug use. Clinicians can then use this information in measurement-based care to assess the effectiveness of therapy and provide additional treatments if necessary.

Neurotype Inc. is developing NeuromarkR™ to monitor Visual Evoked Potentials and generate clinician-friendly reports to guide treatment of SUD. Unlike subjective measures used to manage SUD, such as counting withdrawal symptoms or relying on patient craving reports, NeuromarkR™ objectively measures brain responses in a 6-minute scan. The objective measurements provided by NeuromarkR are 2-3x more stable and reliable than self-reported craving measures, which can fluctuate minute-by-minute.

Evidence Based

Treatment Companion

Based on more than 30 years of peer- reviewed research

Objective, reliably measured brain response data

With NeuromarkR™, healthcare providers can deliver preventative psychotherapies and other interventions at the right time, improving the effectiveness of treatment for SUD. Also, incorporating Visual Evoked Potentials during therapy sessions helps engage patients and has shown to improve retention rates and reduce relapses.

Why Recover with Us?

30-40% increase in patient retention and treatment attitudes

Drug use and relapses decrease by more than 25%

Fewer treatment attempts to reach relapse means health cost savings for payers and patients